NCT02941796

Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers

An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics and Safety After Administration of HCP1105 Alone and Co-administration of HGP0918 and HGP0816 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To investigate the pharmacokinetic properties and safety after administration of HCP1105 and co-administration of HGP0918, HGP0816 in healthy male volunteers

Detailed description

The purpose of this study is to investigate the pharmacokinetic properties and safety after administration of HCP1105 and co-administration of HGP0918, HGP0816 in healthy male volunteers

Conditions

• Hyperlipidemias

Interventions

Type	Name	Description
DRUG	HCP1105
DRUG	HCP0918
DRUG	HCP0816

Timeline

• Start date: 2016-06-01
• Primary completion: 2016-07-01
• Completion: 2016-10-01
• First posted: 2016-10-21
• Last updated: 2016-10-21

Locations

1 site across 1 country: South Korea